----item----
version: 1
id: {AF19627C-6869-4663-B2B5-2454C3882179}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/03/27/US quarterly results roundup
parent: {2AE607D7-1EDE-4809-9399-FFC6E9445753}
name: US quarterly results roundup
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: 78a1ca9b-e057-401f-8efa-0d1680a3bf5b

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 3

<p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 29

US quarterly results round-up
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2372

<p><pre>LifeCell Revenues Net loss ($ millions) ($ millions) 1994 1993 1994 1993 3 months 0.32 0.15 (1.04) (0.88) Year 0.98 0.62 (3.73) (3.43) (ended Dec 31st)</pre><p>The revenue increase in LifeCell's 1994 was due to higher sales of its AlloDerm dermal transplant and its alliance with <strong>[C#198600185:Medtronic]</strong> for the development of the LifeCell heart valve. "Although our primary focus has been the burn market, we are expanding our marketing to include periodontal and reconstructive surgery," says CEO Paul Frison. In November, the company raised $5.2 million in a private placement.</p><pre>Biopool International Revenues Net income ($ millions) ($ millions) 1994 1993 1994 1993 3 months 1.47 1.11 0.16 0.20 Year 5.53 4.31 0.71 0.36 (ended Dec 31st)</pre><p>Biopool manufactures medical test kits to diagnose bleeding disorders and assess cardiovascular risk factors, and specialty chemical controls for monitoring therapeutic drugs and drugs-of-abuse. CEO Michael Bick is confident for the company's future, "with over 50 products and three more awaiting approval".</p><pre>Thermo Cardiosystems Revenues Net income ($ millions) ($ millions) 1994 1993 1994 1993 3 months 3.51 1.16 0.79 0.17 Year 10.41 3.52 1.90 0.40 (ended Dec 31st, 1994; Jan 1st, 1994)</pre><p>Thermo Cardiosystems is 57%-owned by Thermo Electron and another of the latter's subsidiaries, Thermedics. Cardiosystem describes the HeartMate pneumatic left ventricular assist device, approved in the US last October, as the only implantable heart-assist device commercially approved by the FDA. The company says it is moving towards providing patients with a permanent alternative to transplantation that is readily available and cost-effective.</p><pre>Cytogen Revenues Net loss ($ millions) ($ millions) 1994 1993 1994 1993 3 months 1.48 1.22 (11.68) (8.45) Year 2.46 10.35 (32.81) (29.23) (ended Dec 31st, 1994; Jan 1st, 1994)</pre><p>In late February, Cytogen completed its purchase of CytoRad which had been agreed in August (see Clinica No 615, p 12). The merger plus the re-acquisition of the marketing rights for OncoScint CR/OV, Cytogen's imaging agent for colorectal and ovarian cancer, increased fourth-quarter losses by one-time charges of $4.1 million. Lower turnover in 1994 is due to the absence of contract revenue from CytoRad which totalled $7.9 million in 1993.</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{2E0CEEF8-031D-43E8-B6AA-07D1397D9E4F}|{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 28

US quarterly results roundup
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950327T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950327T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950327T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT052023
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 29

US quarterly results round-up
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

198600185
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

253792
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T184035Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

78a1ca9b-e057-401f-8efa-0d1680a3bf5b
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T184035Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
